ProCE Banner Activity

My Thoughts on New and Exciting Advances with Immune Checkpoint Blockade for Treatment of Bladder Cancer

Clinical Thought
In this commentary, bladder cancer expert Matthew Galsky, MD, answers questions on the use of immune checkpoint blockade in first-line treatment, switch maintenance, and adjuvant therapy.

Released: November 19, 2020

Expiration: November 18, 2021

Share

Faculty

Matthew Galsky

Matthew Galsky, MD

Professor of Medicine
Director of Genitourinary Medical Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Matthew Galsky, MD

Professor of Medicine
Director of Genitourinary Medical Oncology
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Matthew Galsky, MD, has disclosed that he has received funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Pfizer, and Seattle Genetics and consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, Jansen, Merck, Pfizer, and Seattle Genetics.